Telix Pharmaceuticals Limited
TLX
Positions held
Your positionsTLX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Telix Pharmaceuticals is positioned in the growing biotechnology sector, focusing on innovative therapies that address unmet medical needs, which could lead to significant market opportunities.
- The company has shown a revenue growth of 22.3% year-over-year, indicating strong demand for its products.
- Telix's gross margin stands at 47.57%, reflecting efficient cost management and potential for profitability.
- Despite its growth potential, Telix Pharmaceuticals has a high trailing PE ratio of 107.8, suggesting that the stock may be overvalued compared to earnings.
- The company's free cash flow is negative at -62.6 million, indicating challenges in generating cash from operations.
- Telix has a 'Strong Sell' score of -16.00, with multiple bearish indicators such as MACD bear and RSI≤45, suggesting a downward trend in stock performance.
Fundamentals
| Market cap | $3.74B | Enterprise value | $4.07B | Trailing P/E | 110.10 | Forward P/E | -410.82 |
| PEG | — | Price / book | 7.67 | Beta | 0.56 | Dividend yield | 0.00% |
| Revenue growth | 22.3% | Earnings growth | — | Gross margin | 47.6% | Operating margin | 9.7% |
| Profit margin | 3.8% | ROE | 7.4% | ROA | 2.7% | Debt / equity | 1.19 |
| Current ratio | 2.01 | Free cash flow | -$62.60M | Analyst recommendation | strong_buy | Mean target | $20.45 |
| 52w high | $13.11 | 52w low | $6.28 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $804M | $517M | $333M | $109M | — |
| Op margin | 2.2% | 10.8% | 10.5% | -46.3% | — |
| Net income | -$7.1M | $33.7M | $4.2M | -$104M | — |
| Gross margin | 53.1% | 65.1% | 62.9% | 59.3% | — |
| Gross profit | $426M | $336M | $210M | $64.6M | — |
| Operating income | $18.1M | $55.6M | $35.0M | -$50.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Telix to Host Capital Markets Day in Melbourne on November 4, 2026
2026-10-06 · Telix Doses First US Patients With FDA-Approved Brain Cancer Imaging Drug
2026-10-06 · First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
2026-09-30 · Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
2026-09-30 · Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
2026-09-27 · 3 Australian Growth Stocks With Earnings Growth Up To 65%
2026-09-23 · Telix (ASX:TLX) Shares Could Be 42% Undervalued Following Its ITM Deal
2026-09-23 · Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus
2026-09-22 · Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply
2026-09-22 · Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical Reach
2026-09-21 · Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash
2026-09-21 · Sector Update: Healthcare Stocks Mixed Premarket Monday
Price (daily)
Full chart · RSI · MACD · patterns